[1]孙昱,符达,刘兴党.卵巢癌循环肿瘤细胞的生物学特性及其临床应用进展[J].国际放射医学核医学杂志,2016,40(1):60-64.[doi:10.3760/cma.j.issn.1673-4114.2016.01.012]
 Sun Yu,Fu Da,Liu Xingdang.Progress in biological characteristics and clinical application of circulating tumor cells in ovarian cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):60-64.[doi:10.3760/cma.j.issn.1673-4114.2016.01.012]
点击复制

卵巢癌循环肿瘤细胞的生物学特性及其临床应用进展(/HTML)
分享到:

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
40
期数:
2016年第1期
页码:
60-64
栏目:
出版日期:
2016-01-25

文章信息/Info

Title:
Progress in biological characteristics and clinical application of circulating tumor cells in ovarian cancer
作者:
孙昱 符达 刘兴党
200040 上海, 复旦大学附属华山医院核医学科
Author(s):
Sun Yu Fu Da Liu Xingdang
Department of Nuclear Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
关键词:
卵巢肿瘤肿瘤循环细胞生物学特性诊断预后评估
Keywords:
Ovarian neoplasmsNeoplasm circulating cellsBiological characteristicsDiagnosisPrognostic evaluation
DOI:
10.3760/cma.j.issn.1673-4114.2016.01.012
摘要:
卵巢癌病死率在妇科生殖系统恶性肿瘤中位居第一位,卵巢癌早期无特异性症状,就诊时多数已为晚期,卵巢癌患者高病死率的主要原因是复发和转移。外周血循环肿瘤细胞在肿瘤的复发和转移过程中起重要作用。近年来,循环肿瘤细胞已广泛应用于多种恶性肿瘤的诊断和预后评估。笔者就卵巢癌患者外周血循环肿瘤细胞的生物学特性和应用进展作一综述。
Abstract:
Ovarian cancer ranks first among gynecologic malignancy-related mortalities.Early stage of ovarian cancer does not show specific symptoms,and most cases are diagnosed in advanced stages.The major causes of death are relapse and metastasis,and circulating tumor cells play fundamental roles in these processes.These tumor cells have been widely used recently in detection and prognostic evaluation of many types of malignant tumors.This work reviews the progress in biological characteristics of circulating tumor cells and their clinical application in ovarian cancer.

参考文献/References:

[1] 张旭,史小荣.联合检测肿瘤标志物在卵巢癌诊断中的应用进展[J].中国当代医药,2013,20(10):23-24,31.DOI:10.3969/j.issn.1674-4721.2013.10.009.Zhang X,Shi XR.Application of combined measurement of tumor markers in the diagnosis of ovarian cancer[J].Chin Mod Med,2013,20(10):23-24,31.
[2] Ashworth T.A case of cancer in which cells similar to those in the tumors were seen in the blood after death[J].Aust Med J,1986,14:146-149.
[3] 刘志勇,李宝江.乳腺癌新辅助化疗中循环肿瘤细胞的动态变化及疗效观察[J].中国肿瘤临床,2013,40(23):1431-1435.DOI:10.3969/j.issn.1000-8179.20131252.Liu ZY,Li BJ.Efficacy of neoadjuvant chemotherapy on breast cancer and dynamic changes of circulating tumor cells[J].Chin J Clin Oncol,2013,40(23):1431-1435.
[4] Alva A,Friedlander T,Clark M,et al.Circulating tumor cells as potential biomarkers in bladder cancer[J].J Urol,2015,194(3):790-798.DOI:10.1016/j.juro.2015.02.2951.
[5] Kolostova K,Broul M,Schraml J,et al.Circulating tumor cells in localized prostate cancer:isolation,cultivation in vitro and relationship to T-stage and Gleason score[J].Anticancer Res,2014,34(7):3641-3646.
[6] Poveda A,Kaye SB,Mccormack R,et al.Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer[J].Gynecol Oncol,2011,122(3):567-572.DOI:10.1016/j.ygyno.2011.05.028.
[7] Ning N,Zhan T,Zhang Y,et al.Improvement of specific detection of circulating tumor cells using combined CD45 staining and fluorescence in situ hybridization[J].Clin Chim Acta,2014,433:69-75.DOI:10.1016/j.cca.2014.02.019.
[8] Pearl ML,Zhao Q,Yang J,et al.Prognostic analysis of invasive circulating tumor cells(iCTCs)in epithelial ovarian cancer[J].Gynecol Oncol,2014,134(3):581-590.DOI:10.1016/j.ygyno.2014.06.013.
[9] 李世超,姜军.乳腺癌循环肿瘤细胞生物学特性的研究进展[J].中华肿瘤防治杂志,2012,19(16):1272-1275.DOI:10.16073/j.cnki.cjcpt.2012.16.004.Li SC,Jiang J.Progress in biological characteristics of circulating breast-tumor cells[J].Chin J Cancer Prev Treat,2012,19(16):1272-1275.
[10] Vona G,Sabile A,Louha M,et al.Isolation by size of epithelial tumor cells:a new method for the immunomorphological and molecular characterization of circulatingtumor cells[J].Am J Pathol,2000,156(1):57-63.DOI:10.1016/S0002-9440(10)64706-2.
[11] Choi H,Kim KB,Jeon CS,et al.A label-free DC impedance-based microcytometer for circulating rare cancer cell counting[J].Lab Chip,2013,13(5):970-977.DOI:10.1039/c2lc41376k.
[12] 刘慧颖,殷正丰.上皮间质转化与循环肿瘤细胞[J].肿瘤,2013,33(9):837-840.DOI:10.3781/j.issn.1000-7431.2013.09.015.Liu HY,Yin ZF.Epithelial-mesenchymal transition and circulating tumor cells[J].Tumor,2013,33(9):837-840.
[13] 曾晶,陈东妮,徐进.角蛋白与肿瘤[J].中国细胞生物学学报,2012,34(5):485-492.Zeng J,Chen DN,Xu J.Keratins and Tumors[J].Chin J Cell Biol,2012,34(5):485-492.
[14] 孙凯旋,陈曦,陈说,等.CK7和CA125在人卵巢癌的表达及意义[J].解剖科学进展,2014,20(3):237-239,245.Sun KX,Chen X,Chen S,et al.The expression and significance of CK7 and CA125 in human ovarian cancer[J].Prog Anat Sci,2014,20(3):237-239,245.
[15] 孙红敏,苑中甫.原发及转移性卵巢癌组织中绒毛蛋白、细胞角蛋白7及20的表达[J].郑州大学学报:医学版,2007,42(2):345-347.DOI:10.3969/j.issn.1671-6825.2007.02.053.Sun HM,Yuan ZF.Expression of villin,CK7,and CK20 in primary and metastatic ovarian carcinoma tissue[J].J Zhengzhou Univ(Med Sci),2007,42(2):345-347.
[16] Judson PL,Geller MA,Bliss RL,et al.Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer[J].Gynecol Oncol,2003,91(2):389-394.DOI:10.1016/j.ygyno.2003.08.004.
[17] Ntouroupi TG,Ashraf SQ,Mcgregor SB,et al.Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope[J].Br J Cancer,2008,99(5):789-795.DOI:10.1038/sj.bjc.6604545.
[18] Aktas B,Kasimir-Bauer S,Heubner M,et al.Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy[J].Int J Gynecol Cancer,2011,21(5):822-830.DOI:10.1097/IGC.0b013e318216cb91.
[19] 蒋胜,李力,张玮,等.ERCC1基因mRNA表达水平在卵巢上皮性癌组织中的意义[J].实用妇产科杂志,2009,25(11):661-663.DOI:10.3969/j.issn.1003-6946.2009.11.011.Jiang S,Li L,Zhang W,et al.ERCC1 mRNA expression level as a prognostic factor for epithelial ovarian cancer[J].J Pract Obstet Gynecol,2009,25(11):661-663.
[20] Kuhlmann JD,Wimberger P,Bankfalvi A,et al.ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for Platinum resistance[J].Clin Chem,2014,60(10):1282-1289.DOI:10.1373/clinchem.2014.224808.
[21] Obermayr E,Castillo-Tong DC,Pils D,et al.Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance——a study of the OVCAD consortium[J].Gynecol Oncol,2013,128(1):15-21.DOI:10.1016/j.ygyno.2012.09.021.
[22] He W,Kularatne SA,Kalli KR,et al.Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands[J].Int J Cancer,2008,123(8):1968-1973.DOI:10.1002/ijc.23717.
[23] Feng H,Ghazizadeh M,Konishi H,et al.Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas[J].Jpn J Clin Oncol,2002,32(12):525-529.DOI:10.1093/jjco/hyf111.
[24] 曾新红.卵巢癌组织中GST-π和muc1基因的表达及临床意义[D].北京:中国人民解放军军医进修学院,2004.Zeng XH.GST-π and muc1 gene expression in ovarian carcinoma tissue and their clinical significance[D].Beijing:Chin PLA Postgraduate Med School,2004.
[25] Wang L,Ma J,Liu F,et al.Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance[J].Gynecol Oncol,2007,105(3):695-702.DOI:10.1016/j.ygyno.2007.02.004.
[26] 陆松梅,周琦,张娜,等.EPCAM、MUC16免疫磁珠制备及循环肿瘤细胞检测[J].免疫学杂志,2015,31(6):517-522 DOI:10.13431/j.cnki.immunol.j.20150110Lu SM,Zhou Q,Zhang N,et al.EPCAM and MUC16 immunomagnetic beads preparation and circulating tumor cells detection[J].J Immunol,2015,31(6):517-522.
[27] He S,Li P,Chen X,et al.Fluid biopsy for circulating tumor cells in an occult ovarian cancer patient exhibiting bilateral supraclavicular lymph node metastases:A case report[J].Oncol Lett,2013,6(2):448-452.DOI:10.3892/ol.2013.1364.
[28] Fan T,Zhao Q,Chen JJ,et al.Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer[J].Gynecol Oncol,2009,112(1):185-191.DOI:10.1016/j.ygyno.2008.09.021.
[29] Liu JF,Kindelberger D,Doyle C,et al.Predictive value of circulating tumor cells(CTCs)in newly-diagnosed and recurrent ovarian cancer patients[J].Gynecol Oncol,2013,131(2):352-356.DOI:10.1016/j.ygyno.2013.08.006.
[30] Marth C,Kisic J,Kaern J,et al.Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis[J].Cancer,2002,94(3):707-712.DOI:10.1002/cncr.10250.

相似文献/References:

[1]王立凯,黄丽娟,潘学继,等.人附睾蛋白4单克隆抗体与免放试剂盒的制备及其对卵巢癌诊断的临床价值探讨[J].国际放射医学核医学杂志,2016,40(3):183.[doi:10.3760/cma.j.issn.1673-4114.2016.03.005]
 Wang Likai,Huang Lijuan,Pan Xueji,et al.Preparation of monoclonal antibodies and immunoradiometric assay kit against human epididymis protein 4 and its clinical value in diagnosis of ovarian cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):183.[doi:10.3760/cma.j.issn.1673-4114.2016.03.005]
[2]宋梦姣,韩栋梁,葛宁,等.放疗增敏研究中人卵巢癌SKOV3乏氧细胞模型的建立方法[J].国际放射医学核医学杂志,2014,38(6):356.[doi:10.3760/cma.j.issn.1673-4114.2014.06.002]
 Song Meng-jiao,Han Dong-liang,Ge Ning,et al.The method of establishing the hypoxic SKOV3 cellular model in the research of radiotherapy sensitizer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):356.[doi:10.3760/cma.j.issn.1673-4114.2014.06.002]
[3]李鹏,赵卫威,杨建伟.18F-FDG PET-CT在探测卵巢癌术后复发与转移中的应用价值[J].国际放射医学核医学杂志,2012,36(6):348.[doi:10.3760/cma.j.issn.1673-4114.2012.06.007]
 LI Peng,ZHAO Wei-wei,YANG Jian-wei.18F-FDG PET-CT imaging in the detection of recurrent and metastasis ovarian cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):348.[doi:10.3760/cma.j.issn.1673-4114.2012.06.007]
[4]薛艳,安瑞芳.放射免疫显像在妇科肿瘤中的研究与应用[J].国际放射医学核医学杂志,2006,30(1):36.
 XUE Yan,AN Rui-fang.A research on radioimmunoimaging and its application in diagnosis of gynecological tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(1):36.
[5]史文琴.PET显像在卵巢癌诊断中的作用[J].国际放射医学核医学杂志,2001,25(4):158.
 SHI Wen-qin.The application of 18F-FDG PET in diagnosing of ovarian carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(1):158.
[6]张伟,于丽娟.18F-FDG PET/CT与18F-FDG PET/MRI在卵巢癌临床应用中的进展[J].国际放射医学核医学杂志,2018,(5):441.[doi:10.3760/cma.j.issn.1673-4114.2018.05.010]
 Zhang Wei,Yu Lijuan.Advances in clinical application of 18F-FDG PET/CT and 18F-FDG PET/MRI in ovarian cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(1):441.[doi:10.3760/cma.j.issn.1673-4114.2018.05.010]

备注/Memo

备注/Memo:
收稿日期:2015-07-15;改回日期:。
通讯作者:刘兴党
更新日期/Last Update: 1900-01-01